Eribulin [500mcg/mL (1mg/2mL) IV injection] for second-line treatment of metastatic soft tissue sarcoma
Pre-Cycle 1 | DrugsHTA Council Recommendation (as of 21 July 2022)
As final recommendation, the HTA Council does not recommend the inclusion of eribulin [500mcg/mL (1mg/2mL) IV injection] for second-line treatment of metastatic soft tissue sarcoma in the Philippine National Formulary
Relevant Information
- Status: With Final HTA Council Recommendation and SOH Decision
- Topic Assignment: Internal Assessment
- Policy Question: Should eribulin [500mcg/mL (1mg/2mL) IV injection] for second-line treatment of metastatic soft tissue sarcoma be included in the Philippine National Formulary (PNF)?
- Secretary of Health Decision: Approved as of 12 September 2022
Evidence and Relevant Documents